Adherence to Guidelines for Acute Myocardial Infarction with ST Segment Elevation in a University Hospital of 4th level in Bogota (Colombia) between January 2008 and July 2011
##plugins.themes.bootstrap3.article.details##
Introduction: The ST Segment Elevation Myocardial Infarction (STEMI) is associated with high morbidity and mortality, identifying disease early, and adherence to management guidelines have impacted clinical outcomes in this entity.
Objectives: To evaluate adherence to guidelines in the management of STEMI al Hospital Universitario San Ignacio and to identify 7 performance indicators in the care of patients with STEMI.
Methods: An observational, descriptive, and cross-sectional study. The statistical program STATA 12.1 was used.
Results: We reviewed medical records of 106 patients with median age 61 years, which comorbidities was: Dyslipidemia, hypertension, smoking, Mortality during the hospitalization 14.29%. Of the 7 variables making measures EKG within 10 minutes (74.5%), making lipid profile within 24 hours of admission by almost (80 %), ASA Bolus dose (85%), clopidogrel bolus dose (78.3%), enoxaparin adjusted to weight and age (96 %), beta-blockers (87.7%), ACE inhibitors by almost (84%). Checklist for fibrinolytic therapy in 64 % of patients diagnosed with STEMI were recorded.
Conclusion: Adherence to guidelines in diseases with high morbidity and mortality impact as STEMI should be 100% to ensure better clinical outcomes. Quality indicators that we took to assess adherence to guidelines recommendations were followed in a suitable remarkable level, and excellent (for the use of enoxaparin).
Acute myocardial infarction, ST segment elevation, myocardial reperfusion, thrombolysis, adherence to guidelines, infarto agudo de miocardio, elevación del segmento ST, reperfusión miocárdica, trombolisis, adherencia a guías,
2. Departamento de Cardiología Clínica. Tópicos selectos en enfermedad coronaria. Medellín: Colina; 2008.
3. Verrma S, Fedak PWM, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation. 2002;105:2332-6.
4. Yellon DM, Hansenloy DJ, Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-35.
5. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-Elevation myocardial infarction: a report of the American college of cardiology/American Heart Association task force on practice guidelines (committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation. 2004;110:e82-293.
6. Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/WHF Task Force for the redefinition of myocardial infarction: universal definition of myocardial infarction. Circulation. 2007;116:2634-53.
7. Pinto DS, Southard M, Ciaglo L et al. Door-to-balloon delays with percutaneous coronary intervention in ST-elevation myocardial infarction. Am Heart J. 2006;151:S24-9.
8. Nallamothu BK, Bradley EH, Krumholz AM. Time to treatment in primary percutaneous coronary intervention. N Engl J Med. 2007;357:1631-8.
9. Keeley EC, Boura JA, Grines CL. Primary angioplasty vs intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet. 2003;361:13-20.
10. Antman EM, Hand M, Armstrong PW et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2008;117(2):296-329.
11. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol. 2003;92:824-6.
12. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-7.
13. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1622-32.
14. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet. 1994;343:1115-22.
15. Mandelzweig L et al. The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean basin in 2004. Eur Heart J. 2006;27:2285-93.
16. Heras M et al. Reducción de la mortalidad por infarto agudo de miocardio en un periodo de 5 años. Rev Esp Cardiol. 2006;59:200-8.
17. Felices-Abad F et al. Indicadores de calidad en el síndrome coronario agudo para el análisis del proceso asistencial pre e intrahospitalario. Med Intensive. 2010;34(6):397-417.